BRAF and neoplasm: First of all, studies have shown that NRAS upregulation is another resistance mechanism of BRAF inhibitors and NRAS upregulation may promote the dimerization of RAF, which will cause insensitivity of ERK signaling to drugs, leading to tumor drug resistance (88–90).